Designing Molecules to Decouple Potency From CRS in Autoimmune T-Cell Engagers
- Discover how Y108 is a PEGylated CD3/CD19 T-cell engager derived from the clinically validated blinatumomab platform
- Outline how, by leveraging established PEGylation technology, JY108 is designed to reduce cytokine release syndrome and improve tissue penetration
- Examine preclinical studies in autoimmune disease models that support its potential as a novel B-cell depletion therapy for autoimmune indications